Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Safety of sitagliptin in elderly patients with type 2 diabetes: a pooled analysis of 25 clinical studies.

Round EM, Engel SS, Golm GT, Davies MJ, Kaufman KD, Goldstein BJ.

Drugs Aging. 2014 Mar;31(3):203-14. doi: 10.1007/s40266-014-0155-7.

PMID:
24510656
2.

Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis.

Engel SS, Golm GT, Shapiro D, Davies MJ, Kaufman KD, Goldstein BJ.

Cardiovasc Diabetol. 2013 Jan 3;12:3. doi: 10.1186/1475-2840-12-3.

3.

Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency.

Chan JC, Scott R, Arjona Ferreira JC, Sheng D, Gonzalez E, Davies MJ, Stein PP, Kaufman KD, Amatruda JM, Williams-Herman D.

Diabetes Obes Metab. 2008 Jul;10(7):545-55. doi: 10.1111/j.1463-1326.2008.00914.x. Epub 2008 Jun 1.

PMID:
18518892
4.

Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study.

Williams-Herman D, Johnson J, Teng R, Luo E, Davies MJ, Kaufman KD, Goldstein BJ, Amatruda JM.

Curr Med Res Opin. 2009 Mar;25(3):569-83. doi: 10.1185/03007990802705679 .

PMID:
19232032
5.

Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes.

Fonseca V, Staels B, Morgan JD 2nd, Shentu Y, Golm GT, Johnson-Levonas AO, Kaufman KD, Goldstein BJ, Steinberg H.

J Diabetes Complications. 2013 Mar-Apr;27(2):177-83. doi: 10.1016/j.jdiacomp.2012.09.007. Epub 2012 Oct 30.

PMID:
23116881
6.

Hypoglycemia in patients with type 2 diabetes from India and Malaysia treated with sitagliptin or a sulfonylurea during Ramadan: a randomized, pragmatic study.

Aravind SR, Ismail SB, Balamurugan R, Gupta JB, Wadhwa T, Loh SM, Suryawanshi S, Davies MJ, Girman CJ, Katzeff HL, Radican L, Engel SS, Wolthers T.

Curr Med Res Opin. 2012 Aug;28(8):1289-96. doi: 10.1185/03007995.2012.707119. Epub 2012 Jul 6.

PMID:
22738801
8.

Efficacy and safety of initial combination therapy with sitagliptin and pioglitazone in patients with type 2 diabetes: a 54-week study.

Yoon KH, Steinberg H, Teng R, Golm GT, Lee M, O'Neill EA, Kaufman KD, Goldstein BJ.

Diabetes Obes Metab. 2012 Aug;14(8):745-52. doi: 10.1111/j.1463-1326.2012.01594.x. Epub 2012 Apr 17.

PMID:
22405352
9.

Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo-controlled 54-week trial in patients with type 2 diabetes.

Dobs AS, Goldstein BJ, Aschner P, Horton ES, Umpierrez GE, Duran L, Hill JS, Chen Y, Golm GT, Langdon RB, Williams-Herman DE, Kaufman KD, Amatruda JM, Ferreira JC.

J Diabetes. 2013 Mar;5(1):68-79. doi: 10.1111/j.1753-0407.2012.00223.x.

PMID:
22742523
10.
11.

Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis.

Williams-Herman D, Round E, Swern AS, Musser B, Davies MJ, Stein PP, Kaufman KD, Amatruda JM.

BMC Endocr Disord. 2008 Oct 27;8:14. doi: 10.1186/1472-6823-8-14.

12.

Lower risk of hypoglycemia with sitagliptin compared to glipizide when either is added to metformin therapy: a pre-specified analysis adjusting for the most recently measured HbA(1c) value.

Krobot KJ, Ferrante SA, Davies MJ, Seck T, Meininger GE, Williams-Herman D, Kaufman KD, Goldstein BJ.

Curr Med Res Opin. 2012 Aug;28(8):1281-7. doi: 10.1185/03007995.2012.703134. Epub 2012 Jul 6.

PMID:
22697277
13.

Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes.

Williams-Herman D, Engel SS, Round E, Johnson J, Golm GT, Guo H, Musser BJ, Davies MJ, Kaufman KD, Goldstein BJ.

BMC Endocr Disord. 2010 Apr 22;10:7. doi: 10.1186/1472-6823-10-7.

14.

The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes.

Yang W, Guan Y, Shentu Y, Li Z, Johnson-Levonas AO, Engel SS, Kaufman KD, Goldstein BJ, Alba M.

J Diabetes. 2012 Sep;4(3):227-37. doi: 10.1111/j.1753-0407.2012.00213.x.

PMID:
22672586
15.

Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes.

Hanefeld M, Herman GA, Wu M, Mickel C, Sanchez M, Stein PP; Sitagliptin Study 014 Investigators.

Curr Med Res Opin. 2007 Jun;23(6):1329-39. Epub 2007 Apr 30.

PMID:
17559733
16.

Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes.

Raz I, Chen Y, Wu M, Hussain S, Kaufman KD, Amatruda JM, Langdon RB, Stein PP, Alba M.

Curr Med Res Opin. 2008 Feb;24(2):537-50. doi: 10.1185/030079908X260925 .

PMID:
18194595
17.

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.

Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P; Sitagliptin Study 035 Group.

Diabetes Obes Metab. 2007 Sep;9(5):733-45. Epub 2007 Jun 26.

PMID:
17593236
18.

Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes.

Scott R, Loeys T, Davies MJ, Engel SS; Sitagliptin Study 801 Group.

Diabetes Obes Metab. 2008 Sep;10(10):959-69. doi: 10.1111/j.1463-1326.2007.00839.x. Epub 2008 Jan 14.

PMID:
18201203
19.

Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.

Mikhail N.

Expert Opin Investig Drugs. 2008 Jun;17(6):845-53. doi: 10.1517/13543784.17.6.845 . Review.

PMID:
18491986
20.

Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial.

Lavalle-González FJ, Januszewicz A, Davidson J, Tong C, Qiu R, Canovatchel W, Meininger G.

Diabetologia. 2013 Dec;56(12):2582-92. doi: 10.1007/s00125-013-3039-1. Epub 2013 Sep 13.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk